• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dupilumab in HIV-positive patients: A case series report of 4 patients.

作者信息

Alawadhi Ameen, Karibayeva Damira, Gottlieb Alice B

机构信息

Icahn School of Medicine at Mount Sinai, New York, New York.

Berkshire Medical Center, Pittsfield, Massachusetts.

出版信息

JAAD Case Rep. 2020 Oct 9;6(12):1356-1359. doi: 10.1016/j.jdcr.2020.09.023. eCollection 2020 Dec.

DOI:10.1016/j.jdcr.2020.09.023
PMID:33304976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7718127/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af06/7718127/57eaece77301/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af06/7718127/6f2e1b7bb270/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af06/7718127/fc664b5b8f72/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af06/7718127/0192fbfd4a7b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af06/7718127/57eaece77301/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af06/7718127/6f2e1b7bb270/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af06/7718127/fc664b5b8f72/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af06/7718127/0192fbfd4a7b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af06/7718127/57eaece77301/gr4.jpg

相似文献

1
Dupilumab in HIV-positive patients: A case series report of 4 patients.度普利尤单抗治疗HIV阳性患者：4例病例系列报告
JAAD Case Rep. 2020 Oct 9;6(12):1356-1359. doi: 10.1016/j.jdcr.2020.09.023. eCollection 2020 Dec.
2
Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.特应性皮炎患者接受度普利尤单抗治疗相关结膜炎的风险因素。
JAMA Dermatol. 2018 Oct 1;154(10):1208-1211. doi: 10.1001/jamadermatol.2018.2690.
3
Rosacea associated with dupilumab therapy.与度普利尤单抗治疗相关的酒渣鼻。
J Dermatolog Treat. 2021 Feb;32(1):114-116. doi: 10.1080/09546634.2019.1624683. Epub 2019 Jun 9.
4
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.度普利尤单抗为未达到研究者全球评估（IGA）的清除或几乎清除的特应性皮炎患者提供了重要的临床获益：两项 III 期临床试验数据的汇总分析。
Br J Dermatol. 2019 Jul;181(1):80-87. doi: 10.1111/bjd.17791. Epub 2019 Apr 11.
5
Dupilumab: A review of its use in the treatment of atopic dermatitis.度普利尤单抗：治疗特应性皮炎的研究进展。
J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36. doi: 10.1016/j.jaad.2017.12.022.
6
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理（LIBERTY AD CHRONOS）：一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
7
Long-term off-label dupilumab in pediatric atopic dermatitis: A case series.儿童特应性皮炎长期使用度普利尤单抗的超说明书用药：病例系列
Pediatr Dermatol. 2019 Jan;36(1):85-88. doi: 10.1111/pde.13697. Epub 2018 Oct 18.
8
JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients.JAK抑制剂作为度普利尤单抗难治性重度特应性皮炎的挽救疗法：6例病例系列
JAAD Case Rep. 2023 Feb 4;33:81-83. doi: 10.1016/j.jdcr.2023.01.020. eCollection 2023 Mar.
9
Dupilumab for treatment of atopic dermatitis.度普利尤单抗治疗特应性皮炎。
Expert Rev Clin Pharmacol. 2018 May;11(5):467-474. doi: 10.1080/17512433.2018.1449642. Epub 2018 Mar 20.
10
Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: A retrospective case series.度普利尤单抗用于特应性皮炎中局部糖皮质激素撤药的管理：一项回顾性病例系列研究
JAAD Case Rep. 2018 Oct 3;4(9):860-862. doi: 10.1016/j.jdcr.2018.06.012. eCollection 2018 Oct.

引用本文的文献

1
Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective.合并症和特殊人群的中重度特应性皮炎患者的生物制剂和小分子治疗：意大利视角
Dermatol Reports. 2023 Sep 13;16(2):9839. doi: 10.4081/dr.2023.9839. eCollection 2024 Jun 14.
2
Young HIV-positive male patient with severe atopic dermatitis on dupilumab and SARS-CoV-2 infection, a pioneer hypothesis.一名感染严重特应性皮炎的HIV阳性年轻男性患者使用度普利尤单抗及感染了SARS-CoV-2，一个初步假设。
Int J Dermatol. 2021 Apr;60(4):514-515. doi: 10.1111/ijd.15499. Epub 2021 Feb 28.

本文引用的文献

1
Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection.度普利尤单抗在一名患有特应性皮炎、重度哮喘和HIV感染患者中的应用。
Dermatol Ther. 2020 Nov;33(6):e14159. doi: 10.1111/dth.14159. Epub 2020 Sep 9.
2
Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients.度普利尤单抗治疗后皮肤T细胞淋巴瘤进展：7例患者病例回顾
J Am Acad Dermatol. 2020 Jul;83(1):197-199. doi: 10.1016/j.jaad.2020.03.050. Epub 2020 Mar 27.
3
Use of dupilumab in patients who are HIV-positive: report of four cases.
度普利尤单抗在HIV阳性患者中的应用：4例报告。
Br J Dermatol. 2019 Dec;181(6):1311-1312. doi: 10.1111/bjd.18222. Epub 2019 Oct 9.
4
Inflammatory dermatoses in human immunodeficiency virus.人类免疫缺陷病毒相关的炎症性皮肤病
Indian J Sex Transm Dis AIDS. 2017 Jul-Dec;38(2):113-120. doi: 10.4103/ijstd.IJSTD_22_17.
5
Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.特应性皮炎管理指南：第 1 节。特应性皮炎的诊断和评估。
J Am Acad Dermatol. 2014 Feb;70(2):338-51. doi: 10.1016/j.jaad.2013.10.010. Epub 2013 Nov 27.
6
The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers--a review and hypothesis.人类免疫缺陷病毒1型（HIV-1）感染期间辅助性T细胞1（Th1）和辅助性T细胞2（Th2）细胞因子平衡的变化表明对病毒蛋白存在过敏反应，这种反应可能被Th2细胞因子抑制剂和免疫反应调节剂逆转——一篇综述与假说
Virus Genes. 2004 Jan;28(1):5-18. doi: 10.1023/B:VIRU.0000012260.32578.72.
7
The relationship between HIV infection and atopic dermatitis.人类免疫缺陷病毒感染与特应性皮炎之间的关系。
Curr Allergy Asthma Rep. 2002 Jul;2(4):275-81. doi: 10.1007/s11882-002-0050-x.